Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Chauhan, Bhupendrasinh F ^a,b   Chartrand, Caroline ^b   Ni Chroinin, Muireann ^c   Milan, Stephen J ^d   Ducharme, Francine M ^b,e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c University College Cork   (Ireland)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; SALMETEROL; ANTIASTHMATIC AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL FUMARATE; SALBUTAMOL; SALMETEROL XINAFOATE;

ASTHMA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; ANALOGS AND DERIVATIVES; CHILD; CHRONIC DISEASE; DISEASE COURSE; DRUG COMBINATION; FEMALE; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; CHILD; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORMOTEROL FUMARATE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALMETEROL XINAFOATE;

EID: 84964695239     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007949.pub2     Document Type: Review

References (199)

1. Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Archives of Disease in Childhood 1999;81(1):45-8.
2. AstraZeneca Pharmaceuticals (SD 039 0719). A six-month, randomized, open-label safety study of Symbicort® (160/4.5 mcg) compared to Pulmicort Turbuhaler® in asthmatic children aged 6 to 11 years. http://www.astrazenecaclinicaltrials.com (accessed 4 January 2008).
3. Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD, et al. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy Asthma Proceedings 2010;31(1):26-39.
4. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Oxis and Pulmicort turbuhaler in the management of asthma OPTIMA international study group. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax 2000;55(Suppl 3):A4.
5. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. For the Oxis and Pulmicort Turbuhaler in the Management of Asthma (OPTIMA) international study group. Thorax 2000; Vol. 55, issue Suppl 3:s5.
6. Bisgaard H, Hultquist C. Budesonide/formoterol for maintenance and as needed - a new approach to asthma management in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):1060.
7. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy - a new strategy in pediatric asthma. Chest 2006;130(6):1733-43.
8. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis. European Respiratory Journal. 2001;18(Suppl 33):517s.
9. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal 2001;18(Suppl 33):331s.
10. O'Byrne PM. Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology 2007;119(6):1332-6.
11. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Sandtröm T, Tattersfield AE, Runnerström EM, et al. Addition of formoterol Turbuhaler® to budesonide Tubuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal 2001;18(Suppl 33):330s.
12. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma [see comment]. American Journal of Respiratory and Critical Care Medicine 2005;171(2):129-36.
13. SD-039-0673 Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as Single Therapy in patients with mild-moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com/Submission/View?id=1007 (accessed 8 May 2015).
14. Carroll WD, Jones PW, Boit P, Clayton S, Cliff I, Lenney W. Childhood evaluation of salmeterol tolerance - A double-blind randomized controlled trial. Pediatric Allergy and Immunology 2010 Mar;21(2 PART 1):336-44.
15. De Blic J, Ogorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatric Allergy and Immunology 2009; Vol. 20, issue 8:763-71.
16. Glaxo Smith Kline (SAM104926). A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE™) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS™) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose. http://ctr.gsk.co.uk (accessed 14 January 2008).
17. AstraZeneca Pharmaceuticals (SD 039 0725). A twelve-week, randomized, double-blind, double-dummy, active-controlled study of Symbicort® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma. http://astrazenecagrouptrials.pharmacm.com/Submission/View?id=966 (accessed 8 May 2015).
18. AstraZeneca Pharmaceuticals (SD 039 0725). A twelve-week, randomized, double-blind, double-dummy, active-controlled study of Symbicort® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma. http://www.astrazenecaclinicaltrials.com (accessed 4 January 2008).
19. Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Sträter C, Steinkamp G, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatric Pulmonology 2009;44(11):1132-42.
20. Heuck C, Heickendorff L, Wolthers OD. A randomized controlled trial of short term growth and collagen turnover in asthmatics with inhaled formoterol and budesonide. Archives of Disease of Childhood 2000;83(4):334-9.
21. Heuck C, Heickendorff L, Wolthers OD, Sygehus S. Short term growth and collagen turnover in asthmatics treated inhaled formoterol and budesonide. European Respiratory Society Annual Congress; 1999 Oct 9-13; Madrid. 1999:364.
22. Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrims progress: the effect of salmeterol in older children with chronic severe asthma. Respiratory Medicine 1995;89(6):435-40.
23. Lemanske RFJr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. New England Journal of Medicine 2010;362(11):975-85.
24. Lenney W, McKay AJ, Tudur Smith C, Williamson PR, James M, Price D. Management of asthma in school age children on therapy. Health Technology Assessment 2013; Vol. 17, issue 4:1-238.
25. Dorinsky P, Emmett A, Sutton L. Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs ICS alone [Abstract]. European Respiratory Journal 2004;24(Suppl 48):308s.
26. House K, Dorinsky PM, Stauffer J, Schoaf L, Ellsworth A. The safety of fluticasone propionate/salmeterol Diskus(R) in pediatric patients ages 4-11 with asthma [Abstract]. Chest 2004;126(Suppl 4):911S.
27. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of Allergy, Asthma, and Immunology 2005;95(1):66-71.
28. SAS30031 A randomized, double-blind, 12-week trial evaluating the safety of the fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in symptomatic pediatric subjects (4-11 years) with asthma. http://www.gsk-clinicalstudyregister.com/study/SAS30031?study_ids=SAS30031#rs (accessed 8 May 2015).
29. Scott C, Wu W, Ellsworth A, Crim C. Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):1057.
30. Meijer GG, Postma DS, Mulder PG, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. American Journal of Respiratory and Critical Care Medicine 1995;152:1887-92.
31. AstraZeneca SD 039 0682. A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler®(budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) in children with asthma. http://www.astrazenecaclinicaltrials.com (accessed 4 January 2008).
32. Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonology Pharmacology Therapeutics 2008;21(1):152-9.
33. AstraZeneca A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort®pMDI (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) in children with asthma. http://www.astrazenecaclinicaltrials.com (accessed 4 January 2008).
34. Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonology Pharmacology Therapeutics 2008; Vol. 21, issue 1:152-9.
35. Murray CS, Custovic A, Lowe LA, Aldington S, Williams M, Beasley R, et al. Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma. Allergy and Asthma Proceedings 2010; Vol. 31, issue 5:415-21.
36. Glaxo Smith Kline (SFA100316). A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in pediatric and in adolescent subjects with activity-induced bronchospasm. http://ctr.gsk.co.uk (accessed 30 April 2008).
37. Murray JJ, Waitkus-Edwards KR, Yancey SW. Evaluation of fluticasone propionate and fluticasone propionate/salmeterol combination on exercise in pediatric and adolescent patients with asthma. Open Respiratory Medical Journal 2011;5:11-8.
38. Ortega-Cisnero M, Maldonado-Alaniz ML, Rosas Vargas MA, Sierra-Monge JJL. Salmeterol and inhaled beclomethasone versus high dose inhaled beclomethasone in the control of pediatric patients with moderate asthma. Annals of Allergy, Asthma and Immunology 1998;80:131.
39. Glaxo Smith Kline (SFA100314). A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in pediatric and in adolescent subjects with activity-induced bronchospasm. http://www.ctr.gsk.co.uk (accessed 16 May 2008).
40. Pearlman D, Qaqundah P, Matz J, Yancey SW, Stempel DA, Ortega HG. Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. Pediatric Pulmonology 2009 May; Vol. 44, issue 5:429-35.
41. Pohunek P, Kuna P, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal 2004;24(Suppl 48):379s.
42. Pohunek P, Kuna P, Jorup C, Boeck KD. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology 2006;17(6):458-65.
43. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology 2004;15(1):32-9.
44. Pohunek P, Kuna P, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal 2004;24(Suppl 48):379s.
45. Pohunek P, Kuna P, Jorup C, Boeck KD. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology 2006;17(6):458-65.
46. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology 2004;15(1):32-9.
47. Glaxo Smith Kline (SALMP/AH91/D89). A phase III, multi-centre, double-blind, placebo controlled, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate (Serevent™) 50 micrograms BD via the Diskhaler™ when added to the existing treatment of moderate to severe asthmatic children. www.ctr.gsk.co.uk (accessed 9 June 2008).
48. Russell G, Williams DAJ, Weller P, Price JF. Salmeterol xinafoate on children on high dose inhaled steroids. Annals of Allergy, Asthma and Immunology 1995;75(5):423-28.
49. Rutkowski R, Rutkowski K, Bilbin M, Rutkowska J, Milewski R, Kosztyla-Hojna B. Childhood asthma - Effect of regular and on demand formoterol with budesonide treatment twice a day. International Review of Allergology and Clinical Immunology 2009;15(3-4):52-8.
50. Dorinsky P, Emmett A, Sutton L. Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) versus ICS alone [Abstract]. European Respiratory Journal 2004;24(Suppl 48):308s.
51. Glasxo Smith Kline (SAM40012). A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments: 1) salmeterol/fluticasone propionate (SFC) (50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4-11 years with asthma. http://www.gsk-clinicalstudyregister.com/study/SAM40012?study_ids=SAM40012#rs (accessed 8 May 2015).
52. Dorinsky P, Emmett A, Sutton L. Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs ICS alone [Abstract]. European Respiratory Journal 2004;24(Suppl 48):308s.
53. Glaxo Smith Kline (SAM40012). A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments: 1) salmeterol/fluticasone propionate (SFC) (50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4-11 years with asthma. http://www.gsk-clinicalstudyregister.com/study/SAM40012#rs (accessed 8 May 2015) 2005.
54. Glaxo Smith Kline (SAM40100). Randomised, double-blind, comparator study to demonstrate the superiority of salmeterol/fluticasone propionate combination DISKUS™ 50/100mcg bd over fluticasone propionate DISKUS™/ACCUHALER™ 200mcg bd with respect to airway physiology in asthmatic children treated for 6 weeks. http://ctr.gsk.co.uk (accessed 4 January 2008).
55. AstraZeneca Pharmaceuticals (SD 039 0714). Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mcg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200 mcg b.i.d. metered dose) in steroid-using asthmatic adolescent patients. A double-blind, double-dummy, randomised, parallel group, phase III, multicentre study. http://www.astrazenecaclinicaltrials.com (accessed 21 February 2006).
56. AstraZeneca Pharmaceuticals (SD 039 0718). A twelve-week, randomized, double-blind, double-dummy trial of Symbicort® (40/4.5 mcg) versus its mono-products (budesonide and formoterol) in asthmatic children aged six to fifteen years. http://www.astrazenecaclinicaltrials.com (accessed 4 January 2008).
57. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99(5):655-9.
58. Stelmach I, Grzelewskia T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulmonology Pharmacology and Therapeutics 2007;20(6):691-700.
59. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P, et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology 2008;121(2):383-9.
60. AstraZeneca Pharmaceuticals (SD 039 0353). Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid-using asthmatic children. http://www.astrazenecaclinicaltrials.com (accessed 25 April 2008).
61. Tal A, Simon G, Vermeulen JH. Symbicort® (budesonide and formoterol in a single inhaler) is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18-23; San Francisco. 2001.
62. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/Formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology 2002;34(5):342-50.
63. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Rapid and sustained improvements in lung function and symptom control with budesonide/ formoterol in adolescent asthma. European Respiratory Journal 2001;18(Suppl 33):494s.
64. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Symbicort (budesonide and formoterol in a single inhaler) improves lung function in children with asthma. International Paediatric Respiratory and Allergy Congress, April 1-4; Prague. 2001:85.
65. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Symbicort (budesonide and formoterol in a single inhaler) is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress April 1-4; Prague. 2001:84-5.
66. Vermeulen JH, Simon G, Tal A. Symbicort® (budesonide and formoterol in a single inhaler) improves lung function in asthmatic children aged 4-17 years. Annual Thoracic Society 97th International Conference; 2001 May 18-23; San Francisco. 2001.
67. Teper AM, Zaragoza SM, Lubovich S, Rodriguez VA, Venalago C, Kofman CD, et al. Effect of fluticasone propionate (FP) with or without salmeterol (S) on bronchial reactivity (BR) in children with mild to moderate persistent asthma [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, 2005:[C47] [Poster: A5].
68. Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, Brackel HJ, Gerrits GP, Hop WC, et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. American Journal of Respiratory and Critical Care Medicine 2010;182(10):1221-7.
69. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerribijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. American Journal of Respiratory and Critical Care Medicine 1998;158(1):213-9.
70. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerribijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. American Journal of Respiratory and Critical Care Medicine 1998;158(1):213-9.
71. Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol turbuhaler(R) when added to inhaled corticosteroid treatment in children with asthma. Pediatric Pulmonology 2004;37(2):122-7.
72. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol Turbuhaler in 6-11 year old children with asthma, not adequately controlled with inhaled corticosteroids. European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002:P2734.
73. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol turbuhaler(r) compared with placebo, in children (6-11 yr) with asthma poorly controlled with inhaled corticosteroids [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A746.
74. Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol turbuhaler(R) when added to inhaled corticosteroid treatment in children with asthma. Pediatric Pulmonology 2004;37(2):122-7.
75. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol Turbuhaler in 6-11 year old children with asthma, not adequately controlled with inhaled corticosteroids. European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm. 2002:P2734.
76. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol turbuhaler(r) compared with placebo, in children (6-11 yr) with asthma poorly controlled with inhaled corticosteroids [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A746.
77. Aldington S, Williams M, Weatherall M, Beasley R. Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. Respirology 2006;11(5):638-42.
78. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 mug) in combination in a Diskus(TM) inhaler (Seretide(TM)) is effective and safe in the treatment of steroid-dependent asthma. Respiratory Medicine 1999;93(12):876-84.
79. Bateman ED, Bousquet J, Busse WW, Clark TJ, Gul N, Gibbs M, et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008;63(7):932-8.
80. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Medical Weekly 2004;134(3-4):50-8.
81. Bernstein DI, Hebert J, Cheema A, Murphy KR, Cherrez-Ojeda I, Matiz-Bueno CE, et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy, Asthma, and Clinical Immunology 2011;7(1):21.
82. Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Annals of Allergy, Asthma, and Immunology 2005;95(2):181-9.
83. Boulet LP, Roberts J, Watson EG. Efficacy of salmeterol/fluticasone propionate MDI versus higher dose fluticasone propionate in adolescent and adult asthmatics uncontrolled on fluticasone propionate alone [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [P2799].
84. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clinical and Experimental Allergy 2005;35(6):723-7.
85. Bracamonte T, Schauer U, Emeryk A, Godwood A, Balsara S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus or pressurised metered-dose inhaler in children with asthma. Clinical Drug Investigation 2005;25(1):1-11.
86. Bruce SA, Scherer YK. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence-Based Nursing 2005;8(3):78.
87. Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, et al. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005;23(7):723-31.
88. Buchvald FF, Bisgaard H. Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta 2-agonist of FeNO in asthmatic children on regular inhaled budesonide. European Respiratory Journal 2002;20(Suppl 38):431s.
89. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Current Medical Research and Opinion 2004;20(8):1209-20.
90. Caffey LF, Raissy HH, Marshik P, Kelly HW. A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma. Pediatric Asthma Allergy and Immunology 2005;18(3):123-30.
91. Chen R, Chen M, Xiong J, Yi F, Chi Z, Zhang B. Comparison of heat-sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial. Trials 2010;11:121.
92. Chopra N, Williams M, Rimmer M, Kahl L, Jenkins M, SMO30006 International Study Teams, et al. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. Respiratory Medicine 2005;99(SUPPL 1):S1-S10.
93. Chuchalin A, Kasl M, Bengtsson T, Nihlen U, Rosenborg J. Formoterol used as needed in patients with intermittent or mild persistent asthma. Respiratory Medicine 2005;99(4):461-70.
94. Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respiratory Medicine 2013; Vol. 107, issue 2:180-95.
95. Covar RA, Szefler SJ, Zeiger RS, Sorkness CA, Moss M, Mauger DT, et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. Journal of Allergy and Clinical Immunology 2008 Oct;122(4):741-47.e4.
96. Cowan S, Ernst P, Cartier A, Boulet LP. A population-based evaluation of a regional asthma education centre. Canadian Respiratory Journal 2004;11(1):39-44.
97. Daviskas E, Anderson SD, Shaw J, Eberl S, Seale JP, Yang IA, et al. Mucociliary clearance in patients with chronic asthma: effects of beta agonists. Respirology 2005;10(4):426-35.
98. Delaronde S, Peruccio DL, Bauer BJ. Improving asthma treatment in a managed care population. American Journal of Managed Care 2005;11(6):361-8.
99. Drummond MB, Peters SP, Castro M, Holbrook JT, Irvin CG, Smith LJ, et al. Risk factors for montelukast treatment failure in step-down therapy for controlled asthma. Journal of Asthma 2011;48(10):1051-7.
100. Dubus JC, Mely L, Huiart L, Marguet C, Le Roux P, Reseau de Recherche Clinique en Pneumologie Pediatrique. Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundamental and Clinical Pharmacology 2003;17(5):627-31.
101. Emeryk A, Bracamonte T, Schauer U, Balsara S, Athisegaran R. Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus and MDi in children with asthma [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [P1985].
102. Everden P, Campbell M, Harnden C, McGoldrick H, Bodalia B, Manion V, et al. Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. Pediatric Allergy and Immunology 2004;15(1):40-7.
103. Fardon TC, Lee DK, Hodge MR, Lipworth BJ. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Annals of Allergy, Asthma, and Immunology 2005;95(3):259-65.
104. Grady J, Dockhorn R, Blake K. Effects of inhaled salmeterol powder in adult and adolescent asthmatics using concurrent inhaled corticosteroids [abstract]. European Respiratory Journal 1995;8(Suppl 19):2S.
105. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and Experimental Allergy 2004;34(4):632-8.
106. Holt S, Ryder-Lewis S, Masoli M, Weatherall M, Beasley R. Fixed and adjustable dose asthma action plans based on combination therapy: a pilot study. Respirology 2005;10(4):497-503.
107. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Annals of Allergy, Asthma, and Immunology 2004;92(6):641-8.
108. Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centred outcomes with three classes of asthma medication. European Respiratory Journal 2005;26(1):36-44.
109. Karaman O, Arli O, Uzuner N, Islekel H, Babayigit A, Olmez D, et al. The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children. Allergy and Asthma Proceedings 2007;28(2):204-9.
110. Katial RK, Bernstein D, Prazma CM, Lincourt WR, Stempel DA. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy and Asthma Proceedings 2011; Vol. 32, issue 2:127-36.
111. Kerwin EM, Nathan RA, Meltzer EO, Ortega HG, Yancey SW, Schoaf L, et al. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Respiratory Medicine 2008 Apr;102(4):495-504.
112. Lara-Perez EA. Emprovement of the asthma in children using salmeterol and fluticasone (Seretide) in inhaled combination [Abstract]. XIX World Allergy Organization Congress. 2005:Abstract 861.
113. Levy R, Pinnas J, Milgrom H, Smith J, Yegen U. Safety and efficacy in children with persistent asthma treated with formoterol 10 mug BID delivered via Certihaler: a novel multidose dry-powder inhaler. Pediatric Asthma Allergy and Immunology 2005;18(1):25-35.
114. Li JS, Qaqundah PY, Weinstein SF, Laforce CF, Ellsworth AV, Ortega HG, et al. Fluticasone propionate/salmeterol combination in children with asthma: key cardiac and overall safety results. Clinical Research and Regulatory Affairs 2010;27(3):87-95.
115. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, et al. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clinical Science 2013;124(8):521-8.
116. American Lung Association Asthma Clinical Research. Randomized comparison of strategies for reducing treatment in mild persistent asthma. New England Journal of Medicine 2007;356(20):2027-39.
117. Lundbäck B, Rönmark E, Lindberg A, Jonsson AC, Larsson LG, James M. Asthma control over 3 years in a real-life study. Respiratory Medicine 2009; Vol. 103, issue 3:348-55.
118. Makela MJ, Malmberg LP, Csonka P, Klemola T, Kajosaari M, Pelkonen AS. Salmeterol and fluticasone in young children with multiple-trigger wheeze. Annals of Allergy, Asthma & Immunology 2012;109(1):65-70.
119. Matthys H, Behling B, Behling E. Comparison of formoterol (12 and 6 mug b.i.d.) versus terbutaline (0.5 mg b.i.d.) with equal doses of inhaled budesonide (0.2 mg b.i.d.) in 246 children with mild to moderate asthma. Atemwegs Und Lungenkrankheiten 2004;30(5):251-6.
120. Miraglia del Giudice M, Capristo M, Amelio R, Rocco A, Fusco N, et al. Combined fluticasone propionate/salmeterol (diskus) vs fluticasone propionate (Diskus) in the control of persistent asthma in children. American Thoracic Society 99thInternational Conference; 2003 May 16-21; Seattle. 2003:A117 Poster D78.
121. Miraglia del Giudice M, Piacentini GL, Capasso M, Capristo C, Maiello N, Boner AL, et al. Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respiratory Medicine 2007;101(8):1809-13.
122. Mitchell EA, Didsbury PB, Kruithof N, Robinson E, Milmine M, Barry M, et al. A randomized controlled trial of an asthma clinical pathway for children in general practice. Acta Paediatrica 2005;94(2):226-33.
123. Mitra A, Sims EJ, Mukhopadhyay S, Lipworth BJ. Low-dose inhaled corticosteroid (ICS) confers optimal anti-inflammatory effects while additional bronchodilator activity is afforded by salmeterol in mild persistent asthmatic children [Abstract]. Journal of Allergy and Clinical Immunology 2003;111(2 Suppl):S145.
124. Morice AH, Hochmuth L, Puterman A, Artheden L, Beckman O. Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy & Clinical Immunology 2005;115(2 Suppl):S3.
125. Morice AH, Osmanliev D, Arheden L, Beckman O. Therapeutic equivalence of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy & Clinical Immunology 2005;115(2 Suppl):S2.
126. Morice AH, Hochmuth L, Ekelund J, Thorén A, Puterman AS. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma. Pulmonary Pharmacology & Therapeutics 2008;21(1):32-9.
127. Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Annals of Allergy, Asthma, & Immunology 2004;93(4):351-9.
128. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005;128(4):1910-20.
129. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
130. Nguyen WT, Stewart C, Fisher K, Tolley E, Lew DB, Self TH. Maintenance asthma treatment with fluticasone/salmeterol combination via diskus: effect on outcomes in inner-city children enrolled in Tenncare. Allergy and Asthma Proceedings 2005;26(2):129-34.
131. Noyes K, Bajorska A, Fisher S, Sauer J, Fagnano M, Halterman JS. Cost-effectiveness of the School-Based Asthma Therapy (SBAT). Pediatrics 2013; Vol. 131, issue 3:e709-17.
132. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Oxis and Pulmicort turbuhaler in the management of asthma OPTIMA international study group. Treatment of mild persistent asthma with low doses of inhaled Budesonide alone or in combination with Formoterol. Thorax 2000;55(Suppl 3):A4.
133. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. For the Oxis and Pulmicort Turbuhaler in the Management of Asthma (OPTIMA) international study group. Thorax 2000; Vol. 55, issue Suppl 3:s5.
134. Bisgaard H, Hultquist C. Budesonide/formoterol for maintenance and as needed - a new approach to asthma management in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1060.
135. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis. European Respiratory Journal 2001; Vol. 18, issue Suppl 33:517s.
136. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal 2001; Vol. 18, issue Suppl 33:331s.
137. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. American Journal of Respiratory & Critical Care Medicine 2001;164(8 pt 1):1392-7.
138. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Sandtröm T, Tattersfield AE, Runnerström EM, et al. Addition of formoterol Turbuhaler® to budesonide Tubuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal 2001;18(Suppl 33):330s.
139. Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. Journal of Asthma 2004;41(8):797-806.
140. Peroni DG, Piacentini GL, Bodini A, Ress M, Costella S, Boner AL. Montelukast versus formoterol as second-line therapy in asthmatic children exposed to relevant allergens. Allergy & Asthma Proceedings 2005;26(4):283-6.
141. Peters SP, Prenner BM, Mezzanotte WS, Martin P, O'Brien CD. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy and Asthma Proceedings 2008; Vol. 29, issue 5:499-516.
142. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. American Journal of Respiratory & Critical Care Medicine 2005;172(7):831-6.
143. Covar RA, Szefler SJ, Zeiger RS, Sorkness CA, Moss M, Mauger DT. Factors associated with asthma exacerbations during a long-term clinical trial of controller medication in children. Journal of Allergy and Clinical Immunology 2008;122(4):741-7.
144. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. New England Journal of Medicine 2011 May;364(18):1695-707.
145. Prieto L, Gutierrez V, Perez-Frances C, Badiola C, Lanuza A, Bruno L, et al. Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. Annals of Allergy, Asthma, & Immunology 2005;95(5):452-61.
146. Quirce S, Barcina C, Plaza V, Calvo E, Munoz M, Ampudia R, et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma 2011; Vol. 48, issue 8:839-47.
147. Reddel HK, Gibson PG, Peters MJ, Wark PAB, Sand IB, Hoyos CM, et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respiratory Medicine 2010 Aug; Vol. 104, issue 8:1110-20.
148. Renzi PM, Frassen E, Stat P, Watson EG. Salmeterol/fluticasone propionate diskus (ADVAIR) 50/100mcg bid improves asthma outcomes compared with fluticasone propionate (FLOVENT) diskus 100mcg bid when used as initial maintenance treatment in adult and adolescent subjects with symptomatic persistent asthma [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005:[C33] [Poster: F65].
149. Renzi PM, Howard LA, Ortega HG, Ahmad FF, Chapman KR. Low-dose fluticasone propionate with and without salmeterol in steroid-naive patients with mild, uncontrolled asthma. Respiratory Medicine 2010; Vol. 104, issue 4:510-7.
150. SAM30002 (GSK). A randomised, double blind, double-dummy, parallel-group, twelve week comparison of salmeterol/fluticasone propionate (FP) DISKUS/ACCUHALER 50/100mcg bd. with budesonide 200mcg bd. plus formoterol 4.5mcg bd. (both by breath-activated dry powder inhaler [BADPI]) in adult and adolescent asthmatics. http://www.gsk-clinicalstudyregister.com/study/SAM30002#rs (accessed 13 May 2015).
151. Glaxo Smith Kline. A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. http://ctr.gsk.co.uk (accessed 4 January 2008) 2006.
152. SAS30021 A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma. http://www.gsk-clinicalstudyregister.com/study/SAS30021#ps (accessed 28 April 2008).
153. Schauer U, Bracamonte T, Emeryk A, Balsara S, Athisegaran R. Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg BID delivered via Diskus or CFC - free metered dose inhaler (MDI) in children with asthma [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [P1986].
154. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research & Opinion 2004;20(9):1403-18.
155. Selroos O, Lofroos AB, Pietinalho A, Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study. Respiratory Medicine 2004;98(3):254-62.
156. SFCF3001 A multicentre, randomised, double-blind, double-dummy, parallel-group study to establish equivalence of the salmeterol/fluticasone propionate combination product (50/250g) via either the reservoir powder inhalation device (RPID) or via the Diskus Inhaler over 12 weeks in adolescents and adults with moderate asthma. http://www.gsk-clinicalstudyregister.com/study/RPS30002/SFCF3001#rs (accessed 13 May 2015).
157. SFCF3002 (GSK). A multicentre, randomised, double-blind, double-dummy, parallel-group study to establish equivalence of the fluticasone propionate/salmeterol combination (FSC) product (100/50g) via either the reservoir powder inhalation device (RPID) or via the Diskus inhaler over 12 weeks in children with asthma. http://www.gsk-clinicalstudyregister.com/study/RPS30001/SFCF3002#rs (accessed 13 May 2015).
158. Sienra-Monge JJL, Del Rio-Navarro BE, Alvarez-Amador M, Blandon-Vijil V, Gomez Chico-Velasco R. The quality of life of the asthmatic child caregiver. Gaceta Medica De Mexico 2004;140(2):139-45.
159. Soes-Petersen U, Kava T, Dahle R, Lei Y, Dam N. Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted 'real life' setting. Clinical Respiratory Journal 2011;5(3):173-82.
160. Sorkness CA, Lemanske Jr RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. Journal of Allergy & Clinical Immunology 2007;119(1):64-72.
161. Spector SL, Martin UJ, Uryniak T, O'Brien CD. Budesonide/formoterol pressurized metered-dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. Journal of Asthma 2012; Vol. 49, issue 1:70-7.
162. Stelmach I, Grzelewski T, Jerzynska J, Kuna P. A randomized, double-blind trial on the effect of treatment with montelukast, budesonide, montelukast with budesonide, formoterol with budesonide on lung function and clinical symptoms in children with asthma [Abstract]. Journal of Allergy & Clinical Immunology 2005;115(2 Suppl):S151.
163. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology 2008;121(2):383-9.
164. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine 2004;98(11):1051-62.
165. van den Toorn LM, Prins JB, de Jongste JC, Leman K, Mulder PG, Hoogsteden HC, et al. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respiratory Medicine 2005;99(6):779-87.
166. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. European Respiratory Journal 2005;26(5):819-28.
167. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbuhaler in children. International Journal of Clinical Practice 2003;57(10):852-6.
168. Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Annals of Allergy, Asthma and Immunology 2005;94(1):65-72.
169. You-Ning L, Humphries M, Du X, Wang L, Jiang J. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. International Journal of Clinical Practice 2005;59(7):754-9.
170. Adams NP, Bestall JC, Malouf R, Lasserson TJ, Jones P. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002738.pub2]
171. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
172. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003534.pub3]
173. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Annals of Internal Medicine 2008;149(1):33-42.
174. Bisgaard H. Effect of long-acting β2 agonists on exacerbation rates of asthma in children. Pediatric Pulmonology 2003;36:391-8.
175. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. A national clinical guideline (Revised January 2014). http://sign.ac.uk/pdf/SIGN141.pdf (accessed 14 May 2015).
176. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS. Effect of inhaled glucocorticoids in childhood on adult height. New England Journal of Medecine 2012;367(10):904-12.
177. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
178. Cates CJ, Lasserson TJ, Cates MJ. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006924.pub2]
179. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006922.pub2]
180. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010005.pub2]
181. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002314.pub3]
182. 2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5]
183. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
184. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
185. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2]
186. Global Initiative for Asthma. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015. http://www.ginasthma.org (accessed 14 May 2015).
187. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(557):560.
188. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org, 2011.
189. Lougheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, et al. Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for children six years of age and over, and adults. Canadian Respiratory Journal 2012;19(2):127-64.
190. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006217.pub2]
191. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
192. National Asthma Council, Australia Asthma Management Handbook. www.nationalasthma.org.au (accessed 8 May 2015) 2014.
193. National Asthma Education and Prevention Program. NAEPP Expert Panel Report Guidelines for the Diagnosis and Management of Asthma. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (accessed 13 January 14).
194. NCT01462344 6-Month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI). clinicaltrials.gov (accessed 8 May 2015).
195. Pruteanu A, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009878.pub2]
196. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
197. Sharek PJ, Bergman DA, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001282]
198. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105(2):e23.
199. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007949]